Evidence map›Paper›PMID 32562365›Full record

ArticleJournal of the International AIDS Society2020

Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study.

Annick Bórquez, Katherine Rich, Michael Farrell, Louisa Degenhardt, Rebecca McKetin, Lucy T Tran, Javier Cepeda, Alfonso Silva-Santisteban, Kelika Konda, Carlos F Cáceres and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Annick BórquezDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-6033-9837
Katherine RichYale School of Medicine, Yale University, New Haven, CT, USA.
Michael FarrellNational Drug and Alcohol Research Center, University of New South Wales, Sydney, NSW, Australia.
Louisa DegenhardtNational Drug and Alcohol Research Center, University of New South Wales, Sydney, NSW, Australia.
Rebecca McKetinNational Drug and Alcohol Research Center, University of New South Wales, Sydney, NSW, Australia.
Lucy T TranNational Drug and Alcohol Research Center, University of New South Wales, Sydney, NSW, Australia.
Javier CepedaDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-0304-3172
Alfonso Silva-SantistebanCentro de Investigación Interdisciplinaria en Sexualidad, SIDA y Sociedad, Universidad Peruana Cayetano Heredia, Lima, Peru.
Kelika KondaCentro de Investigación Interdisciplinaria en Sexualidad, SIDA y Sociedad, Universidad Peruana Cayetano Heredia, Lima, Peru.
Carlos F CáceresCentro de Investigación Interdisciplinaria en Sexualidad, SIDA y Sociedad, Universidad Peruana Cayetano Heredia, Lima, Peru.
Sherrie KellyModelling and Biostatistics, Burnet Institute, Melbourne, VIC, Australia.ORCID 0000-0002-6232-5586
Frederick L AlticeNational Drug and Alcohol Research Center, University of New South Wales, Sydney, NSW, Australia.
Natasha K MartinDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
UNSW Sydney · AUUniversidad Peruana Cayetano Heredia · PEBurnet Institute · AUUniversity of Bristol · GBUniversity of California San Diego · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SONIA JAIN · 1994 to 2026
$78.4M
Real-time prediction of emerging drug use epidemics in the United StatesDP2DA049295 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BORQUEZ, ANNICK · 2019 to 2019
$2.4M
Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modelingR01AI147490 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA · 2019 to 2022
$2.3M
Modeling Structural HIV Determinants in Substance Users and related populationsR01DA037773 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA, STRATHDEE, STEFFANIE A. · 2015 to 2017
$1.4M
MODELING THE IMPACT OF A POLICE EDUCATION PROGRAM ON HIV INCIDENCE AMONG PEOPLE WHO INJECT DRUGSK01DA043421 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CEPEDA, JAVIER · 2017 to 2021
$941k
NCATS NIH HHS UL1 TR001442NCATS NIH HHS UL1 TR001863NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI147490NIAID NIH HHS R01AI147490NIDA NIH HHS DP2 DA049295NIDA NIH HHS DP2DA049295NIDA NIH HHS K01 DA043421NIDA NIH HHS K01DA043421NIDA NIH HHS R01 DA037773NIDA NIH HHS R01DA037773NIDA NIH HHS R01DA1104470
6 · The paper itself

Abstract

introductionAmong men who have sex with men (MSM) and transgender women (TW), stimulant use is high and has been associated with an increased risk of HIV infection, suicide and cardiovascular disease (CVD) mortality. We used epidemic modelling to investigate these intersecting health harms among MSM/TW in Lima, Peru and assess whether they could be mitigated by prioritizing HIV pre-exposure prophylaxis (PrEP) and harm reduction interventions among MSM/TW who use stimulants.

methodsWe adapted a dynamic model of HIV transmission among MSM/TW in Lima to incorporate stimulant use and increased HIV risk, suicide and CVD mortality. Among 6% to 24% of MSM/TW using stimulants (mostly cocaine), we modelled an increased risk of unprotected anal sex (RR = 1.35 [95%CI: 1.17 to 1.57]) obtained from local data, and increased risk of suicide (SMR = 6.26 [95%CI: 2.84 to 13.80]) and CVD (SMR = 1.83 [95%CI: 0.39 to 8.57]) mortality associated with cocaine use based on a global systematic review. We estimated the proportion of health harms occurring among MSM/TW who use stimulants in the next year (01-2020/01-2021). We also investigated the 10-year impact (01-2020/01-2030) of: (1) PrEP prioritization for stimulant-using MSM/TW compared to random allocation, and (2) integrating PrEP with a theoretical intervention halving stimulant-associated risk.

resultsMSM/TW in Lima will experience high HIV incidence, suicide mortality and CVD mortality (1.6/100 py, and 0.018/100 py, 0.13/100 py respectively) in 2020. Despite stimulant using MSM/TW comprising an estimated 9.5% (95%CI: 7.8 to 11.5) of all MSM/TW, in the next year, 11% 95%CI (i.e. 2.5% to 97.5% percentile) 10% to 13%) of new HIV infections, 39% (95%CI: 18% to 60%) of suicides and 15% (95%CI: 3% to 44%) of CVD deaths could occur among this group. Scaling up PrEP among all stimulant using MSM/TW could prevent 19% (95%CI: 11% to 31%) more HIV infections over 10 years compared to random allocation. Integrating PrEP and an intervention to halve stimulant-associated risks could reduce new HIV infections by 20% (95%CI: 10% to 37%), suicide deaths by 14% (95%CI: 5% to 27%) and CVD deaths by 3% (95%CI: 0% to 16%) over a decade.

conclusionsMSM/TW who use stimulants experience a disproportionate burden of health harms. Prioritizing PrEP based on stimulant use, in addition to sexual behaviour/gender identity criteria, could increase its impact. Integrated substance use, harm reduction, mental health and HIV care among MSM/TW is needed.

Indexed as

Homosexuality, MalePre-Exposure ProphylaxisTransgender PersonsAnti-HIV AgentsCentral Nervous System StimulantsCocaineFemaleHarm ReductionHIV InfectionsHumansMaleModels, BiologicalPeruSexual and Gender MinoritiesSubstance-Related DisordersSuicideAnti-HIV AgentsCentral Nervous System StimulantsCocaineHIV pre-exposure prophylaxismen who have sex with menmodellingstimulantssuicidetransgender women

Identifiers

PMID32562365
PMCPMC7305413
OpenAlexW3036769618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.